Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma.

Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma.
复制标题

DOI:
10.1155/2010/567351
复制
发表时间:
2010
影响因子:
4.6
通讯作者:
Chiang BL
Chiang BL
中科院分区:
医学3区
文献类型:
--
作者:
Lee JH;Wang LC;Yu HH;Lin YT;Yang YH;Chiang BL

文献摘要

参考文献

被引文献

相似文献

IL-1 R/TLR家族作为潜在的炎症调节因子,通过其作为炎症激活剂或抑制剂的能力而受到相当大的关注。哮喘是一种慢性炎症性疾病,其特征在于气道高反应性、过敏性炎症、血清总IgE水平升高、过敏原特异性IgE水平升高和Th 2细胞因子产生增加。IL-1 RI-IL-1和ST 2-IL-33通路对过敏性炎症至关重要的发现引起了人们对这些受体作为开发支气管哮喘新治疗策略的潜在靶点的兴趣。本文讨论了目前使用的中和单克隆抗体或可溶性受体结构,以消除细胞因子,使用中和单克隆抗体或重组受体拮抗剂,以阻止细胞因子受体,和基因治疗哮喘的实验研究。靶向IL-1 RI-IL-1以及ST 2-IL-33通路可能有望在未来成为一种疾病修饰方法。
The IL-1R/TLR family has been receiving considerable attention as potential regulators of inflammation through their ability to act as either activators or suppressors of inflammation. Asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness, allergic inflammation, elevated serum total, allergen-specific IgE levels, and increased Th2 cytokine production. The discovery that the IL-1RI–IL-1 and ST2–IL-33 pathways are crucial for allergic inflammation has raised interest in these receptors as potential targets for developing new therapeutic strategies for bronchial asthma. This paper discusses the current use of neutralizing mAb or soluble receptor constructs to deplete cytokines, the use of neutralizing mAb or recombinant receptor antagonists to block cytokine receptors, and gene therapy from experimental studies in asthma. Targeting IL-1RI–IL-1 as well as ST2–IL-33 pathways may promise a disease-modifying approach in the future.
DOI: 10.4049/jimmunol.181.7.4780
发表时间: 2008-10-01
影响因子: 4.4
作者:
Kurowska-Stolarska, Mariola;Kewin, Pete;Xu, Damo
通讯作者: Xu, Damo
DOI: 10.4049/jimmunol.0901575
发表时间: 2009-11-15
影响因子: 4.4
作者:
Kurowska-Stolarska, Mariola;Stolarski, Bartosz;Liew, Foo Y.
通讯作者: Liew, Foo Y.
DOI: 10.1517/eoed.8.1.71.21043
发表时间: 2003-05-01
影响因子: 3.4
作者:
Blease, Kate;Lewis, Alan;Raymon, Heather K
通讯作者: Raymon, Heather K
DOI: 10.1084/jem.162.2.501
发表时间: 1985-01-01
影响因子: 15.3
作者:
DOWER, SK;KRONHEIM, SR;URDAL, DL
通讯作者: URDAL, DL
抗 IL-33 抗体治疗可抑制过敏性哮喘小鼠模型的气道炎症
DOI: 10.1016/j.bbrc.2009.06.008
发表时间: 2009-08-14
影响因子: 3.1
作者:
Liu, Xiaojin;Li, Mingcai;Huang, Tian
通讯作者: Huang, Tian